Obinutuzumab: a new class of anti-CD20 monoclonal antibody
Purpose of reviewObinutuzumab is a new anti-CD20 monoclonal antibody which demonstrated clinical superiority compared with rituximab in a recent phase III study. There is a need to better understand how this antibody differs from rituximab and why it could modify the landscape of the treatment of CD20+ malignancies in the near future. Recent findingsAntibody-dependent cellular cytotoxicity plays a critical role in clinical activity of rituximab. To increase antibody-dependent cellular cytotoxicity, a strategy improving the affinity between the Fc portion of the antibody and FcγRIIIa expressed by effector cells has be...
Source: Current Opinion in Oncology - September 1, 2014 Category: Cancer & Oncology Tags: LYMPHOMA: Edited by Bertrand Coiffier and Anne-Sophie Michallet Source Type: research

Antibody drug conjugates
Purpose of reviewAntibody conjugates are a diverse complex class of therapeutics, consisting of a potent cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells or an extracellular target, that are having impact in the clinic. The notion that antibodies directed toward targets on the surface of malignant cells could be used for drug delivery is not new. The more than 30-year history of antibody conjugates is marked by hurdles that have been identified and overcome. Recent findingsTechnology is continuing to evolve the protein and small mo...
Source: Current Opinion in Oncology - September 1, 2014 Category: Cancer & Oncology Tags: LYMPHOMA: Edited by Bertrand Coiffier and Anne-Sophie Michallet Source Type: research

Phosphoinositide 3-kinase inhibitors in lymphoma
Purpose of reviewThe phosphoinositide 3-kinase (PI3K) pathway, with downstream targets including Akt and mammalian target of rapamycin, has been implicated in numerous human cancers, including hematologic malignancies and lymphomas. The development and refinement of PI3K inhibitors directed toward this pathway show promising clinical efficacy. This review will discuss the emerging body of clinical data in lymphoid malignancies and present future directions for research utilizing these inhibitors. Recent findingsThe PI3Kδ inhibitor, idelalisib, has been most widely studied in lymphoma, and has shown promising results ...
Source: Current Opinion in Oncology - September 1, 2014 Category: Cancer & Oncology Tags: LYMPHOMA: Edited by Bertrand Coiffier and Anne-Sophie Michallet Source Type: research

Bruton's tyrosine kinase inhibitors: lessons learned from bench-to-bedside (first) studies
Purpose of reviewTargeted inhibitors of B-cell receptor signaling have emerged as the most promising therapeutic options against non-Hodgkin's lymphoma. The inhibitor agents that target Bruton's tyrosine kinase (BTK) have elicited particularly high enthusiasm given the unprecedented positive responses observed in Phase I trials. The sheer amount of clinical data published since last year now requires reinterpretation in light of recently published findings on BTK. Recent findingsClinical trial data pertaining to various B-cell dyscrasia forms must be interpreted with great caution. The differing response rates reported wit...
Source: Current Opinion in Oncology - September 1, 2014 Category: Cancer & Oncology Tags: LYMPHOMA: Edited by Bertrand Coiffier and Anne-Sophie Michallet Source Type: research

Editorial introductions
No abstract available (Source: Current Opinion in Oncology)
Source: Current Opinion in Oncology - September 1, 2014 Category: Cancer & Oncology Tags: Editorial Introductions Source Type: research